[Bone marrow findings of childhood aplastic anemia

analyses of 140 cases by central reviewers].

Asahito Hama, Ayami Yoshimi, Hirotoshi Sakaguchi, Sayoko Doisaki, Hideki Muramatsu, Akira Shimada, Yoshiyuki Takahashi, Kazue Nozawa, Masafumi Ito, Masahiro Tsuchida, Atsushi Manabe, Akira Ohara, Seiji Kojima

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The revised WHO classification proposed the term "refractory cytopenia of childhood (RCC)" for children with myelodysplastic syndrome (MDS) with a low blast count. The differential diagnosis between RCC and aplastic anemia (AA) is challenging, especially when bone marrow is hypoplastic and there is no detectable chromosomal abnormality. To reveal the difference between AA and RCC with respect to the clinical and biological features, we retrospectively reviewed the bone marrow smears of 140 patients registered for childhood AA-97 study, which were classified into three groups as follows; the AA group was defined as having no morphologically dysplastic changes; the AA-RCC borderline group was defined as having 10% in a single cell lineage. The patients were classified into the AA group (n=96, 69%), AA-RCC borderline group (n=20, 14%) and RCC group (n=24, 17%). Most of the patients in the AA group were classified as having very severe disease, whereas most of the patients in the RCC group were classified as non-severe disease. Only 2 patients in the AA group developed acute myeloid leukemia. The response rate to immunosuppressive therapy did not differ among the 3 groups. To demonstrate whether the two diseases are truly different entities, it is necessary to compare molecular backgrounds between the AA and RCC groups.

Original languageEnglish
Pages (from-to)653-658
Number of pages6
Journal[Rinshō ketsueki] The Japanese journal of clinical hematology
Volume52
Issue number8
Publication statusPublished - Aug 2011
Externally publishedYes

Fingerprint

Aplastic Anemia
Bone Marrow
Myelodysplastic Syndromes
Cell Lineage
Immunosuppressive Agents
Acute Myeloid Leukemia
Chromosome Aberrations
Differential Diagnosis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

[Bone marrow findings of childhood aplastic anemia : analyses of 140 cases by central reviewers]. / Hama, Asahito; Yoshimi, Ayami; Sakaguchi, Hirotoshi; Doisaki, Sayoko; Muramatsu, Hideki; Shimada, Akira; Takahashi, Yoshiyuki; Nozawa, Kazue; Ito, Masafumi; Tsuchida, Masahiro; Manabe, Atsushi; Ohara, Akira; Kojima, Seiji.

In: [Rinshō ketsueki] The Japanese journal of clinical hematology, Vol. 52, No. 8, 08.2011, p. 653-658.

Research output: Contribution to journalArticle

Hama, A, Yoshimi, A, Sakaguchi, H, Doisaki, S, Muramatsu, H, Shimada, A, Takahashi, Y, Nozawa, K, Ito, M, Tsuchida, M, Manabe, A, Ohara, A & Kojima, S 2011, '[Bone marrow findings of childhood aplastic anemia: analyses of 140 cases by central reviewers].', [Rinshō ketsueki] The Japanese journal of clinical hematology, vol. 52, no. 8, pp. 653-658.
Hama, Asahito ; Yoshimi, Ayami ; Sakaguchi, Hirotoshi ; Doisaki, Sayoko ; Muramatsu, Hideki ; Shimada, Akira ; Takahashi, Yoshiyuki ; Nozawa, Kazue ; Ito, Masafumi ; Tsuchida, Masahiro ; Manabe, Atsushi ; Ohara, Akira ; Kojima, Seiji. / [Bone marrow findings of childhood aplastic anemia : analyses of 140 cases by central reviewers]. In: [Rinshō ketsueki] The Japanese journal of clinical hematology. 2011 ; Vol. 52, No. 8. pp. 653-658.
@article{b990c0bb7b154a21964a2af7f212d13e,
title = "[Bone marrow findings of childhood aplastic anemia: analyses of 140 cases by central reviewers].",
abstract = "The revised WHO classification proposed the term {"}refractory cytopenia of childhood (RCC){"} for children with myelodysplastic syndrome (MDS) with a low blast count. The differential diagnosis between RCC and aplastic anemia (AA) is challenging, especially when bone marrow is hypoplastic and there is no detectable chromosomal abnormality. To reveal the difference between AA and RCC with respect to the clinical and biological features, we retrospectively reviewed the bone marrow smears of 140 patients registered for childhood AA-97 study, which were classified into three groups as follows; the AA group was defined as having no morphologically dysplastic changes; the AA-RCC borderline group was defined as having 10{\%} in a single cell lineage. The patients were classified into the AA group (n=96, 69{\%}), AA-RCC borderline group (n=20, 14{\%}) and RCC group (n=24, 17{\%}). Most of the patients in the AA group were classified as having very severe disease, whereas most of the patients in the RCC group were classified as non-severe disease. Only 2 patients in the AA group developed acute myeloid leukemia. The response rate to immunosuppressive therapy did not differ among the 3 groups. To demonstrate whether the two diseases are truly different entities, it is necessary to compare molecular backgrounds between the AA and RCC groups.",
author = "Asahito Hama and Ayami Yoshimi and Hirotoshi Sakaguchi and Sayoko Doisaki and Hideki Muramatsu and Akira Shimada and Yoshiyuki Takahashi and Kazue Nozawa and Masafumi Ito and Masahiro Tsuchida and Atsushi Manabe and Akira Ohara and Seiji Kojima",
year = "2011",
month = "8",
language = "English",
volume = "52",
pages = "653--658",
journal = "[Rinsho ketsueki] The Japanese journal of clinical hematology",
issn = "0485-1439",
publisher = "Nihon Rinsho Ketsueki Gakkai/Japan Society of Clinical Hematology",
number = "8",

}

TY - JOUR

T1 - [Bone marrow findings of childhood aplastic anemia

T2 - analyses of 140 cases by central reviewers].

AU - Hama, Asahito

AU - Yoshimi, Ayami

AU - Sakaguchi, Hirotoshi

AU - Doisaki, Sayoko

AU - Muramatsu, Hideki

AU - Shimada, Akira

AU - Takahashi, Yoshiyuki

AU - Nozawa, Kazue

AU - Ito, Masafumi

AU - Tsuchida, Masahiro

AU - Manabe, Atsushi

AU - Ohara, Akira

AU - Kojima, Seiji

PY - 2011/8

Y1 - 2011/8

N2 - The revised WHO classification proposed the term "refractory cytopenia of childhood (RCC)" for children with myelodysplastic syndrome (MDS) with a low blast count. The differential diagnosis between RCC and aplastic anemia (AA) is challenging, especially when bone marrow is hypoplastic and there is no detectable chromosomal abnormality. To reveal the difference between AA and RCC with respect to the clinical and biological features, we retrospectively reviewed the bone marrow smears of 140 patients registered for childhood AA-97 study, which were classified into three groups as follows; the AA group was defined as having no morphologically dysplastic changes; the AA-RCC borderline group was defined as having 10% in a single cell lineage. The patients were classified into the AA group (n=96, 69%), AA-RCC borderline group (n=20, 14%) and RCC group (n=24, 17%). Most of the patients in the AA group were classified as having very severe disease, whereas most of the patients in the RCC group were classified as non-severe disease. Only 2 patients in the AA group developed acute myeloid leukemia. The response rate to immunosuppressive therapy did not differ among the 3 groups. To demonstrate whether the two diseases are truly different entities, it is necessary to compare molecular backgrounds between the AA and RCC groups.

AB - The revised WHO classification proposed the term "refractory cytopenia of childhood (RCC)" for children with myelodysplastic syndrome (MDS) with a low blast count. The differential diagnosis between RCC and aplastic anemia (AA) is challenging, especially when bone marrow is hypoplastic and there is no detectable chromosomal abnormality. To reveal the difference between AA and RCC with respect to the clinical and biological features, we retrospectively reviewed the bone marrow smears of 140 patients registered for childhood AA-97 study, which were classified into three groups as follows; the AA group was defined as having no morphologically dysplastic changes; the AA-RCC borderline group was defined as having 10% in a single cell lineage. The patients were classified into the AA group (n=96, 69%), AA-RCC borderline group (n=20, 14%) and RCC group (n=24, 17%). Most of the patients in the AA group were classified as having very severe disease, whereas most of the patients in the RCC group were classified as non-severe disease. Only 2 patients in the AA group developed acute myeloid leukemia. The response rate to immunosuppressive therapy did not differ among the 3 groups. To demonstrate whether the two diseases are truly different entities, it is necessary to compare molecular backgrounds between the AA and RCC groups.

UR - http://www.scopus.com/inward/record.url?scp=84855993877&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855993877&partnerID=8YFLogxK

M3 - Article

VL - 52

SP - 653

EP - 658

JO - [Rinsho ketsueki] The Japanese journal of clinical hematology

JF - [Rinsho ketsueki] The Japanese journal of clinical hematology

SN - 0485-1439

IS - 8

ER -